Telehealth abortion access upheld—for now

A federal judge in Louisiana just left one of the biggest post-Roe v. Wade abortion workarounds standing: patients can still have a telehealth visit and get mifepristone by mail under current federal rules, at least for now. Judge David C. Joseph refused Louisiana’s request for an immediate nationwide block on April 7, 2026. (npr.org) The judge did not bless telehealth abortion on the merits. He paused the case and told the Food and Drug Administration to finish a safety review of mifepristone, then report back to the court in six months. (stateline.org) Mifepristone is the first drug in the two-pill regimen commonly used for medication abortion and for some miscarriage care. The Food and Drug Administration first approved it in 2000, and the agency later expanded how it can be prescribed and dispensed. (fda.gov) The key federal change came in January 2023, when the Food and Drug Administration formally removed the in-person dispensing requirement from the mifepristone safety program. That let certified pharmacies dispense the drug and let patients receive it by mail after remote visits where state law allowed it. (fda.gov) Louisiana and other Republican-led states want that clock turned back. Their lawsuit asks the court to restore the old in-person rule and shut down pharmacy and mail distribution tied to telemedicine, which would reach far beyond Louisiana’s own borders. (georgetown.edu) That reach matters because telehealth is no longer a niche channel. The Society of Family Planning’s #WeCount project found that telehealth accounted for 27% of abortions in the United States in the first half of 2025, up from 25% at the end of 2024. (societyfp.org) The Supreme Court already touched mifepristone once in 2024, but only on who was allowed to sue. In Food and Drug Administration v. Alliance for Hippocratic Medicine, the justices said the anti-abortion doctor groups in that case lacked standing, so the federal rules stayed in place. (supremecourt.gov) This Louisiana case takes a different path by using states as plaintiffs instead of private groups. That gives abortion opponents another shot at the same federal policy, even after the Supreme Court’s 2024 ruling left the underlying Food and Drug Administration framework intact. (npr.org) The map underneath this fight has gotten stranger since Roe fell in June 2022. According to the Guttmacher Institute, 8 states now have shield laws that specifically extend protections to telehealth abortion providers, and 22 states plus Washington, District of Columbia, have some form of reproductive health shield law. (guttmacher.org) (law.ucla.edu) Those shield laws are built for exactly this kind of cross-border fight. A doctor in New York can consult by video with a patient in a ban state and mail pills under New York’s protections, while officials in the patient’s home state argue the care violates their own law. (cdt.org) So the immediate result is simple and the long-term result is not. Mail delivery of mifepristone after telehealth visits survives nationwide today, but the judge’s order leaves open the possibility that the Food and Drug Administration could face pressure to tighten the rules later this year. (apnews.com) (npr.org)